Drug intelligence / Profile preview

henagliflozin

Development stage: Phase 4
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Henagliflozin is a small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor developed for the treatment of type 2 diabetes mellitus. It works by inhibiting SGLT2 in the renal proximal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering blood glucose levels. Clinical studies have shown that henagliflozin as monotherapy or in combination with metformin provides effective glycemic control, reduces body weight and blood pressure, and is generally well tolerated. The drug has been approved in China for adult patients with type 2 diabetes to improve glycemic control[3][4][6][9].

Brand names: Rui Qin瑞沁
Other names: 脯氨酸恒格列净Proline Henggliflozin TabletsHenggliflozin Tablets

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on henagliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on henagliflozin.

Explore the full profile